Cinclus Pharma (ST:CINPHA) — Market Cap & Net Worth
Market Cap & Net Worth: Cinclus Pharma (CINPHA)
Cinclus Pharma (ST:CINPHA) has a market capitalization of $57.59 Million (Skr535.18 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #21471 globally and #387 in its home market, demonstrating a -7.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cinclus Pharma's stock price Skr11.50 by its total outstanding shares 46537789 (46.54 Million). Also see CINPHA total asset value for a full breakdown of the balance sheet.
Cinclus Pharma Market Cap History: 2024 to 2026
Cinclus Pharma's market capitalization history from 2024 to 2026. Data shows change from $107.08 Million to $57.59 Million (-43.78% CAGR). Also see cash efficiency ratio of Cinclus Pharma for how efficiently the company converts equity into cash flow.
Cinclus Pharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cinclus Pharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check CINPHA stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.68x
Cinclus Pharma's market cap is 1.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $107.08 Million | $4.58 Million | -$168.03 Million | 23.38x | N/A |
| 2025 | $96.46 Million | $57.47 Million | -$183.97 Million | 1.68x | N/A |
Competitor Companies of CINPHA by Market Capitalization
Companies near Cinclus Pharma in the global market cap rankings as of September 19, 2026. Review Cinclus Pharma tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cinclus Pharma by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Cinclus Pharma Historical Marketcap From 2024 to 2026
Between 2024 and today, Cinclus Pharma's market cap moved from $107.08 Million to $ 57.59 Million, with a yearly change of -43.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr57.59 Million | -40.29% |
| 2025 | Skr96.46 Million | -9.92% |
| 2024 | Skr107.08 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Cinclus Pharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $57.59 Million USD |
| MoneyControl | $57.59 Million USD |
| MarketWatch | $57.59 Million USD |
| marketcap.company | $57.59 Million USD |
| Reuters | $57.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cinclus Pharma
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in … Read more